CERITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H36ClN5O3S
Molecular Weight	558.135
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(=O)C(C)C)=N3

InChI

InChIKey=VERWOWGGCGHDQE-UHFFFAOYSA-N

InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

HIDE SMILES / InChI

Molecular Formula	C28H36ClN5O3S
Molecular Weight	558.135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755s000lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=2467504; https://www.novartis.ca/sites/www.novartis.ca/files/zykadia_scrip_e.pdf

Ceritinib is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). Ceritinib is approved by FDA and is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Ceritinib also targets insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
ALK tyrosine kinase receptor 25 Target ID: CHEMBL4247 Sources: https://www.novartis.ca/sites/www.novartis.ca/files/zykadia_scrip_e.pdf	Antagonist 2778		0.15 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Non-small cell lung cancer 206 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755s000lbl.pdf	Primary		Approved 8429	ZYKADIA Approved Use ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Launch Date 1.39872961E12

C_max

Value	Dose	Co-administered	Analyte	Population
800 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
16500 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 37 years (range: 29–67 years) n = 6 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 37 years (range: 29–67 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (all grades, 100%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 37 years (range: 29–67 years) n = 6 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 37 years (range: 29–67 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (all grades, 33%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125	unhealthy, 37 years (range: 29–67 years) n = 6 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 37 years (range: 29–67 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/26020125	Other AEs: Vomiting, Abdominal pain... Other AEs: Vomiting (all grades, 100%) Abdominal pain (all grades, 17%) Fatigue (all grades, 33%) Blood creatinine increased (all grades, 50%) Decreased appetite (all grades, 50%) Alanine aminotransferase increased (all grades, 33%) Aspartate aminotransferase increased (all grades, 33%) Neutropenia (all grades, 33%) Rash (all grades, 50%) Maculopapular rash (17%) Stomatitis (33%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/	unhealthy, 39 years (range: 34–61 years) n = 4 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 39 years (range: 34–61 years) Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/	DLT: Lipase increased... Dose limiting toxicities: Lipase increased (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/
750 mg 1 times / day steady, oral MTD Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 53 years n = 255 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 53 years Sex: M+F Population Size: 255 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Pneumonitis... Other AEs: Pneumonitis... AEs leading to discontinuation/dose reduction: Pneumonitis (grade 3-4, 3%) Other AEs: Pneumonitis (all grades, 4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
750 mg 1 times / day steady, oral MTD Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 54 years (range: 22- 81 years) n = 189 Health Status: unhealthy Condition: ALK-positive NSCLC patients Age Group: 54 years (range: 22- 81 years) Sex: M+F Population Size: 189 Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	DLT: ALT increased, AST increased... Disc. AE: Nausea, Diarrhea... Other AEs: Nausea, Diarrhea... Dose limiting toxicities: ALT increased (grade 3-4, 34%) AST increased (grade 3-4, 21%) AEs leading to discontinuation/dose reduction: Nausea (grade 3-4, 2.6%) Diarrhea (grade 3-4, 4.8%) Vomiting (grade 3-4, 5%) GGT increased (grade 3-4, 49%) Creatinine increased (grade 3-4, 4.2%) Amylase increased (grade 3-4, 8%) Lipase increased (grade 3-4, 6%) Other AEs: Nausea (all grades, 69%) Diarrhea (all grades, 85%) Vomiting (all grades, 67%) Abdominal pain (all grades, 40%) Abdominal pain upper (all grades, 40%) Abdominal discomfort (all grades, 40%) Epigastric discomfort (all grades, 40%) Abdominal pain (grade 3-4, 3.7%) Abdominal pain upper (grade 3-4, 3.7%) Abdominal discomfort (grade 3-4, 3.7%) Epigastric discomfort (grade 3-4, 3.7%) Constipation (all grades, 20%) Dyspepsia (all grades, 15%) Gastroesophageal reflux disease (all grades, 15%) Dysphagia (all grades, 15%) Dyspepsia (grade 3-4, 0.5%) Gastroesophageal reflux disease (grade 3-4, 0.5%) Dysphagia (grade 3-4, 0.5%) Fatigue (all grades, 45%) Asthenia (all grades, 45%) Fatigue (grade 3-4, 7%) Asthenia (grade 3-4, 7%) Non-cardiac chest pain (all grades, 21%) Non-cardiac chest pain (grade 3-4, 1.1%) Back pain (all grades, 19%) Back pain (grade 3-4, 1.6%) Pyrexia (all grades, 19%) Pain in extremity (all grades, 13%) Musculoskeletal pain (all grades, 11%) Musculoskeletal pain (grade 3-4, 0.5%) Pruritus (all grades, 11%) Pruritus (grade 3-4, 0.5%) Decreased appetite (all grades, 34%) Decreased appetite (grade 3-4, 1.1%) Weight loss (all grades, 24%) Weight loss (grade 3-4, 3.7%) Rash (all grades, 21%) Dermatitis acneiform (all grades, 21%) Rash maculo-papular (all grades, 21%) Rash (grade 3-4, 1.1%) Dermatitis acneiform (grade 3-4, 1.1%) Rash maculo-papular (grade 3-4, 1.1%) Headache (all grades, 19%) Headache (all grades, 0.5%) Dizziness (grade 3-4, 12%) Dizziness (grade 3-4, 1.1%) QT interval prolonged (all grades, 12%) QT interval prolonged (grade 3-4, 2.6%) Pericardial effusion (all grades, 4.2%) Pericarditis (all grades, 4.2%) Pericardial effusion (grade 3-4, 1.6%) Pericarditis (grade 3-4, 1.6%) Cough (all grades, 25%) Pneumonia (serious, 4%) Pleural effusion (serious, 4%) ALT increased (all grades, 91%) AST increased (all grades, 86%) GGT increased (all grades, 84%) Alkaline phosphatase increased (all grades, 81%) Alkaline phosphatase increased (grade 3-4, 12%) Creatinine increased (all grades, 77%) Hyperglycemia (all grades, 53%) Hyperglycemia (grade 3-4, 10%) Hypophosphatemia (all grades, 38%) Hypophosphatemia (grade 3-4, 3.7%) Amylase increased (all grades, 37%) Hyperbilirubinemia (all grades, 15%) Hyperbilirubinemia (grade 3-4, 0.5%) Lipase increased (all grades, 13%) Anemia (all grades, 67%) Anemia (grade 3-4, 4.2%) Neutropenia (all grades, 27%) Neutropenia (grade 3-4, 2.1%) Thrombocytopenia (all grades, 16%) Thrombocytopenia (grade 3-4, 1%) Vision decreased (4%) Blurred vision (4%) Photopsia (4%) Accommodation disorder (4%) Presbyopia (4%) Visual acuity reduced (4%) Vitreous floaters (4%) Bradycardia (4%) Hepatotoxicity (2%) Renal failure (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 707 CYP2B6 810 CYP2C19 1478 CYP2E1 882 P-gp 1461 BCRP 699 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OCT2 647 OCT1 512	CYP3A 191 P-gp 1537 BCRP 561 OCT1 327 OAT2 115 OATP1B1 406 OATP2B1 104	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 0.2 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 2 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 2 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 20 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 30 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 5 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 70 uM]
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A 191	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=20 Page: -	major	yes (co-administration study) Comment: Ceritinib is primarily metabolized by CYP3A, and is also a reversible and time-dependent inhibitor of CYP3A in vitro. Coadministration of ketoconazole (a strong CYP3A inhibitor) 200 mg twice daily for 14 days and a single dose of 450 mg ceritinib increased ceritinib AUC by 2.9- fold and Cmax by 20% in healthy subjects. Coadministration of rifampin (a strong CYP3A inducer) 600 mg daily for 14 days and a single dose of 750 mg ceritinib decreased ceritinib AUC by 70% and Cmax by 44% in healthy subjects. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=20 Page: -
OAT2 115	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OATP2B1 104	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OCT1 327	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=37 Page: -	yes
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	yes	no (co-administration study) Comment: Ko143 (a BCRP inhibitor) had a smaller effect on the reduction of efflux ratio to 121 at 3 μM ceritinib, indicating that an in vivo DDI study with a BCRP inhibitor is not necessary. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000PharmR.pdf#page=27 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:78432	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:78432
ChemicalBook	CB82652832	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82652832
MolPort	MolPort-035-395-774	https://www.molport.com/shop/molecule-link/MolPort-035-395-774
Selleck Chemicals	ldk378	http://www.selleckchem.com/products/ldk378.html
ZINC	ZINC000096272772	http://zinc15.docking.org/substances/ZINC000096272772

PubMed

Title	Date	PubMed
		252160836
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.	2007 Jan 2	17185414
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.	2013 Jul 25	23742252
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	2014 Jun	24675041
Overcoming drug resistance in ALK-rearranged lung cancer.	2014 Mar 27	24670172
Ceritinib in ALK-rearranged non-small-cell lung cancer.	2014 Mar 27	24670165
The EML4-ALK oncogene: targeting an essential growth driver in human cancer.	2015	25971657
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.	2015 Jul	26020125

Patents

Sample Use Guides

In Vivo Use Guide

750 mg orally once daily. Administer ZYKADIA on an empty stomach (i.e., do not administer within 2 hours of a meal).

Route of Administration: Oral

In Vitro Use Guide

In vitro Ceritinib inhibited ALK+-NSCLC cell lines (H3112 and H2228) with GIC50 values of 6.3 and 3.8 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:49:59 UTC 2023` Edited by `admin` on `Sat Dec 16 09:49:59 UTC 2023`
Record UNII	K418KG2GET
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CERITINIB

Official Name

English

CERITINIB [MI]

Common Name

English

2,4-PYRIMIDINEDIAMINE, 5-CHLORO-N4-(2-((1-METHYLETHYL)SULFONYL)PHENYL)-N2-(5-METHYL-2-(1-METHYLETHOXY)-4-(4-PIPERIDINYL)PHENYL)-

Systematic Name

English

CERITINIB [ORANGE BOOK]

Common Name

English

CERITINIB [USAN]

Common Name

English

ceritinib [INN]

Common Name

English

NVP-LDK-378-NX

Code

English

LDK-378

Code

English

5-CHLORO-N4-(2-((1-METHYLETHYL)SULFONYL)PHENYL)-N2-(5-METHYL-2-(1-METHYLETHOXY)-4- (PIPERIDIN-4-YL)PHENYL)PYRIMIDINE-2,4-DIAMINE

Systematic Name

English

ZYKADIA

Brand Name

English

LDK378

Code

English

5-CHLORO-N2-(5-METHYL-4-(PIPERIDIN-4-YL)-2-(PROPAN-2-YLOXY)PHENYL)-N4-(2-(PROPANE-2- SULFONYL)PHENYL)PYRIMIDINE-2,4-DIAMINE

Systematic Name

English

NVP-LDK378-NX

Code

English

CERITINIB [JAN]

Common Name

English

CERITINIB [VANDF]

Common Name

English

Ceritinib [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C141136